Cellares defends its cell therapy platform after Bristol Myers ends partnership

Cellares, a cell therapy manufacturing startup, responded to criticism from Bristol Myers Squibb after the drugmaker terminated their agreement.

Bristol Myers withdrew, saying Cellares' commercial manufacturing technology did not meet its standards.

Cellares denied the allegation, asserting its technology is robust and the contract termination was unwarranted.